NewcelX Appoints Dr. Julien Boisdron to Strengthen Scientific Advisory Board
NewcelX Ltd. (NASDAQ: NCEL), a leading biotechnology company focused on developing innovative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases, has announced the appointment of Dr. Julien Boisdron, MD. Dr. Boisdron has extensive experience in diabetes management and big pharma leadership in Switzerland, and he will join NewcelX's Scientific Advisory Board (SAB).
Expertise in Diabetes Innovation
Dr. Boisdron brings over two decades of global leadership in diabetes care. He currently serves as Chief Medical Officer for a prominent multinational pharmaceutical company based in Switzerland. His extensive background includes:
- Strategic development of next-generation diabetes technologies
- Overseeing clinical programs and real-world evidence initiatives
- Innovations in connected care and advanced insulin management systems
- Integration of therapeutic and digital solutions to enhance patient outcomes
Role on the Scientific Advisory Board
As a member of NewcelX's SAB, Dr. Boisdron will provide vital strategic guidance for the development of IsletRx, a lead therapeutic program focusing on stem-cell-derived islet cell therapy aimed at insulin-dependent Type 1 Diabetes. This therapeutic area is a primary clinical focus for NewcelX.
Dr. Boisdron will advise on various facets of the IsletRx program, including:
- Translational strategy
- Patient adoption considerations
- Health-system integration
- Global commercialization frameworks
“I am honored to join NewcelX's Scientific Advisory Board and to collaborate on advancing next-generation therapies for diabetes,” said Dr. Boisdron. “NewcelX's integrated platform, combining cell therapy and neuroscience innovations, provides a compelling foundation to move potentially transformative treatments closer to patients.”
Statements from NewcelX Leadership
Prof. Michel Revel, Chief Scientific Officer of NewcelX, expressed, “Welcoming Dr. Boisdron to our advisory board strengthens NewCelX's leadership in metabolic and regenerative medicine. His extensive experience in diabetes care and global medical leadership will enrich our strategic direction as we advance our IsletRx program.”
According to Ronen Twito, Executive Chairman & CEO of NewcelX, “Type 1 Diabetes is the core focus of NewcelX and a key priority in our clinical development strategy. Dr. Boisdron's deep expertise in diabetes innovation, clinical strategy, and global healthcare systems will significantly enhance our efforts as we move IsletRx closer to clinical trials.”
About NewcelX Ltd.
Founded in Zurich, Switzerland, NewcelX Ltd. (NASDAQ: NCEL) is at the forefront of biotechnology, developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company leverages advanced stem-cell technologies combined with neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as ALS and Type 1 Diabetes.
Forward-Looking Statements
This announcement includes forward-looking statements governed by the Private Securities Litigation Reform Act of 1995. Statements regarding anticipated contributions from Dr. Boisdron and the potential for NewcelX to offer functional solutions for insulin-dependent diabetes depend on various factors and uncertainties that may cause actual results to differ materially.
For detailed information on risks and uncertainties affecting NewcelX, please refer to the company’s annual report filed with the U.S. Securities and Exchange Commission (SEC).